Program
Bimatoprost Ophthalmic Solution
Also written as “bimatoprost ophthalmic solution 0.03%”, “bimatoprost ophthalmic solution 0.01%” and “Bimatoprost ophthalmic solution 0.01% YSBP”.
Its studies are mostly in Glaucoma, Open-Angle · Hypotrichosis · Alopecia Areata, led by 3 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| AbbVie | 70 open or running | phase 4since Nov 30, 2009 | Nov 30, 2009 | none ahead |
| Amneal Pharmaceuticals | 11 open or running | phase 1since Feb 12, 2024 | Feb 12, 2024 | none ahead |
| YS Life Science | 11 open or running | phase 3since Jun 16, 2026 | Jun 16, 2026 | Nov 1, 2027phase 3 · NCT07661329 |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Nov 30, 2009First study: phase 4 study in Alopecia AreataNew to AbbVieAbbVie · NCT01023841 · 71 enrolled · United States, Brazil
- Feb 5, 2010Phase 2 study in Eyelash HypotrichosisAbbVie · NCT01064882 · 104 enrolled · United States
- Dec 2, 2010Phase 4 study in Glaucoma, Open-AngleAbbVie · NCT01253902 · 164 enrolled · United States, Canada
- Oct 6, 2011Phase 4 study in HypotrichosisAbbVie · NCT01448525 · 88 enrolled · United States
- Feb 10, 2012Phase 4 study in Glaucoma, Open-AngleAbbVie · NCT01547598 · 135 enrolled · Canada
- Jun 25, 2014Phase 4 study in Facial RhytidesAbbVie · NCT02176356 · 116 enrolled · United States
- May 2, 2016Phase 4 study in Glaucoma, Open-AngleAbbVie · NCT02863705 · 118 enrolled · Korea, Republic of
- Feb 12, 2024Amneal Pharmaceuticals’ first study: phase 1 study in Glaucoma, Open-AngleNew to Amneal PharmaceuticalsAmneal Pharmaceuticals · NCT06267274 · 240 planned · United States
- Jun 16, 2026YS Life Science’s first study: phase 3 study in Glaucoma, Open-AngleNew to YS Life ScienceYS Life Science · NCT07661329 · 600 planned · United States, India
Ahead
- Nov 1, 2027Primary completion: phase 3 study in Glaucoma, Open-AngleYS Life Science · NCT07661329
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 9 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07661329Glaucoma, Open-Angle · United States, India | 3 | Recruiting | YS Life Science | Nov 1, 2027 | 600 |
| NCT06267274Glaucoma, Open-Angle · United States | 1 | Recruiting | Amneal Pharmaceuticals | Mar 1, 2025 | 240 |
| NCT02863705Glaucoma, Open-Angle · Korea, Republic of | 4 | Completed | AbbVie | Jul 25, 2018 | 118 |
| NCT02176356Facial Rhytides · United States | 4 | Completed | AbbVie | May 3, 2015 | 116 |
| NCT01547598Glaucoma, Open-Angle · Canada | 4 | Completed | AbbVie | Jul 2013 | 135 |
| NCT01448525Hypotrichosis · United States | 4 | Completed | AbbVie | Apr 2012 | 88 |
| NCT01253902Glaucoma, Open-Angle · United States, Canada | 4 | Completed | AbbVie | Oct 2011 | 164 |
| NCT01064882Eyelash Hypotrichosis · United States | 2 | Completed | AbbVie | Jul 2010 | 104 |
| NCT01023841Alopecia Areata · United States, Brazil | 4 | Completed | AbbVie | Nov 2, 2012 | 71 |
How it is read
Names in the registry
- “bimatoprost ophthalmic solution 0.03%”, 4 entries
- “bimatoprost ophthalmic solution 0.01%”, 2 entries
- “Bimatoprost ophthalmic solution 0.01% YSBP”, 1 entry
- “Bimatoprost Ophthalmic Solution, 0.01%”, 1 entry
- “Bimatoprost ophthalmic solution 0.01%”, 1 entry
Conditions, from the studies’ own filings
- Glaucoma, Open-Angle, 5 studies
- Hypotrichosis, 2 studies
- Alopecia Areata, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.